Recently, CN-105 was tested in a mouse model of AD (APP/PS1/APOE4TR mice) and the results showed that amyloid pathology and spatial learning deficits were reduced when the peptide treatment started in younger (14-18 weeks of age) but not older (25-28 weeks of age) mice [215]. This evidence concerns the gene PSEN1 and amyloidosis.